Managing menopausal symptoms effectively requires understanding real-world prescribing trends and treatment persistence. Recent clinical registry data provides critical insights into how clinicians prescribe systemic hormone therapy for women diagnosed with menopause. Furthermore, evaluating initiation rates helps healthcare providers address care gaps and optimize long-term patient care.
Key Factors Influencing Systemic Hormone Therapy Initiation
In a large cohort analysis of over 300,000 menopausal women, approximately 21.7% initiated treatment within one year of diagnosis. Notably, younger age significantly increased the likelihood of starting therapy. In addition, patients with a history of hysterectomy or concurrent local hormone use showed higher initiation rates. Conversely, clinical conditions like obesity and diabetes correlated with lower treatment initiation.
Treatment Formulations and Duration of Systemic Hormone Therapy
Among women starting treatment, estrogen plus progestogen combinations were the most common choice at 52.5%. Meanwhile, estrogen-alone regimens accounted for 32.4%, and progestogen-alone options represented 15.1%. However, real-world treatment continuation remains low across all groups. The median duration of the first treatment episode was only 6.6 months. Consequently, fewer than 39% maintained therapy at 12 months. Specifically, prior hysterectomy and local hormone use reduced the risk of early discontinuation.
Clinical Implications for Patient Care
These findings highlight significant disparities in treatment persistence and access. Therefore, clinicians must address early drop-off rates through targeted patient counseling and personalized symptom management. In summary, bridging these clinical gaps will ensure consistent, comprehensive care for menopausal women.
Frequently Asked Questions
Q1: What proportion of women initiate systemic hormone therapy after a menopause diagnosis?
Approximately 21.7% of eligible women initiate treatment within one year of receiving a menopause diagnosis.
Q2: What is the median duration of the initial hormone therapy episode?
The median duration for the first treatment episode is 6.6 months, with under 39% continuing at 12 months.
Q3: Which factors lower the risk of early treatment discontinuation?
A history of hysterectomy and concurrent local hormone use significantly reduce the risk of early discontinuation.
References
- Sriprasert I et al. Initiation and Duration of Systemic Hormone Therapy for Menopausal Symptoms. Obstet Gynecol. 2026 Jul 27. doi: 10.1097/AOG.0000000000006386. PMID: 42492961.